Anti-KRAS antibodies can be used in combination with anti-EGFR antibody (Cetuximab) in KRAS wildtype advanced colorectal cancer (CRC) patients to concurrently kill tumor cells that has developed resistance to anti-EGFR therapy due to acquired KRAS mutation. This evidence concerns the gene KRAS and colorectal carcinoma.